The global myasthenia gravis treatment market size was valued at around USD 1,011.1 million in 2017 and is expected to grow at a CAGR of 12.1% during the forecast period, growing development of novel drugs such as monoclonal antibodies is driving the growth of the global market. Moreover, growing awareness regarding treatment and increasing number of clinical facilities are also boosting myasthenia gravis treatment market growth, globally.
According to the Myasthenia Gravis Foundation of America, myasthenia gravis is one of the most common primary disorders of neuromuscular transmission. Around 14 to 20 out of every 100,000 people in the United States suffer from myasthenia gravis. While myasthenia gravis can affect people of all ages, it is more common in women under 40 and men older than 60. According to Elsevier, 1,283 New Zealanders are affected by a neuromuscular disorder, amounting to a collective prevalence of 30.25 cases per 100,000.
|Market Size||USD 1,011.1 million|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
The global myasthenia gravis treatment market share has been classified into four key regions, namely North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA).
North America is expected to hold the largest market share, owing to the increasing number of drug manufacturers and rising awareness about the long-term effects of muscular dystrophy. Moreover, increasing government funding for the treatment of this disease in North America is also favoring market growth. According to National Centers for Advancing Translation Science, in the U.S., around 1 in 500,000 people suffer from disorders each year.
Asia Pacific is expected to be the fastest growing region due to the increasing awareness about neuromuscular disorders and enhancement in healthcare reforms across countries such as Malaysia, India, Indonesia, and China. Apart from this, the increasing geriatric population is supporting market growth on account of the increasing prevalence of the disorder.
Europe accounts for the second largest share in the global market, owing to the increasing prevalence of autoimmune disorders in the region. For instance, As per Muscular Dystrophy UK, about 15 in every 100,000 people in the U.K. are affected by myasthenia gravis.
The Middle East region is projected to witness steady growth, owing to the extensive advancement of healthcare infrastructure and growing R&D activities in the healthcare sector.
The global myasthenia gravis treatment market share can be segmentation by type, treatment, end-user, and region.
Based on type, the market can be segmented into ocular MG, congenital MG, and transient neonatal MG. The ocular MG segment is expected to account for a prominent market share, owing to the high prevalence of the disease.
Based on treatment, the market can be segmented into medication, surgery, Autologous Hematopoietic Stem Cell Transplantation (HSCT), plasmapheresis & intravenous immunoglobulin, and others. Among these, the autologous hematopoietic stem cell transplantation segment is expected to hold a significant market share, owing to the therapy’s cost-effectiveness.
Based on end-user, the market can be segmented into hospitals, clinics, academic research institutes, and others. Among these, the hospitals segment is expected to hold a noteworthy market share during the forecast period.
Some of the key players in the global myasthenia gravis treatment market are